TGFB1 抗体 (AA 101-200)
Quick Overview for TGFB1 抗体 (AA 101-200) (ABIN1385286)
抗原
See all TGFB1 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 101-200
-
特异性
- The antibody targets the Latency-associated peptide (LAP), which is a cleavage product of the Transforming growth factor beta-1 proprotein (TGFB1)
-
交叉反应
- 人, 小鼠
-
纯化方法
- Purified by Protein A.
-
免疫原
- KLH conjugated synthetic peptide derived from human TGF beta 1/LAP
-
亚型
- IgG
-
-
-
-
应用备注
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500 -
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 μg/μL
-
缓冲液
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
有效期
- 12 months
-
-
- TGFB1 (Transforming Growth Factor, beta 1 (TGFB1))
-
别名
- TGFB1
-
背景
-
Synonyms: Transforming growth factor beta-1 proprotein, CED, LAP, DPD1, TGFB, TGFbeta, TGF-beta-1, TGFB1
Background: Latency-associated peptide: Required to maintain the Transforming growth factor beta-1 (TGF-beta-1) chain in a latent state during storage in extracellular matrix. Associates non-covalently with TGF-beta-1 and regulates its activation via interaction with 'milieu molecules', such as LTBP1, LRRC32/GARP and LRRC33/NRROS, that control activation of TGF-beta-1. Interaction with LRRC33/NRROS regulates activation of TGF-beta-1 in macrophages and microglia (Probable). Interaction with LRRC32/GARP controls activation of TGF-beta-1 on the surface of activated regulatory T-cells (Tregs). Interaction with integrins (ITGAV:ITGB6 or ITGAV:ITGB8) results in distortion of the Latency-associated peptide chain and subsequent release of the active TGF-beta-1.
-
基因ID
- 7040
-
UniProt
- P01137
-
途径
- EGFR Signaling Pathway, Dopaminergic Neurogenesis, Cellular Response to Molecule of Bacterial Origin, Glycosaminoglycan Metabolic Process, Regulation of Leukocyte Mediated Immunity, Regulation of Muscle Cell Differentiation, Positive Regulation of Immune Effector Process, Cell-Cell Junction Organization, Production of Molecular Mediator of Immune Response, Ribonucleoside Biosynthetic Process, Skeletal Muscle Fiber Development, Regulation of Carbohydrate Metabolic Process, Protein targeting to Nucleus, Autophagy, Cancer Immune Checkpoints
抗原
-